FAT1
FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
Overview
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming CDK4/6 Inhibition. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.99, genetic association 0.18, somatic mutation 0.98, animal model 0.44). IntOGen calls it a driver in 45 cohorts (15 activating, 30 loss-of-function), covering Acute Myeloid Leukaemia, Angiosarcoma, Anal Squamous Cell Carcinoma, Basal Cell Carcinoma, Burkitt Lymphoma, Bladder/Urinary Tract and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
- 1 · What it is
FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
- 2 · What goes wrong in cancer
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact. Location: Cell membrane; Nucleus (UniProt).
- 3 · How drugs use it
No product in this corpus aims at FAT1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:3595 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14517 (protein name, function text, keywords and locations (REST API)); CIViC gene FAT1 (1 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0)); Open Targets ENSG00000083857 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.53, colorectal cancer 0.59, oesophageal cancer 0.59, urinary bladder cancer 0.60, cervical cancer 0.53, melanoma 0.62 (GraphQL API, CC0)); IntOGen FAT1 (driver in 45 cohorts (Act 15, LoF 30); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact. Location: Cell membrane; Nucleus (UniProt). Locus 4q35.2 (HGNC).
- Head and neck squamous cell carcinoma: Open Targets association 0.70 with head and neck squamous cell carcinoma (MONDO_0010150); IntOGen driver in 5 cohorts (HNSC)
- Lung cancer: Open Targets association 0.68 with lung cancer (MONDO_0008903)
- Bladder & urothelial cancer: Open Targets association 0.60 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLADDER, BLCA, UTUC)
- Breast cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (BRCA)
- Oesophageal cancer: Open Targets association 0.59 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA, ESCC)
- Cervical cancer: Open Targets association 0.53 with cervical cancer (MONDO_0002974); IntOGen driver in 2 cohorts (CESC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 15 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 30 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FAT1" OR ABSTRACT:"FAT1" OR TITLE:"FAT atypical cadherin 1" OR ABSTRACT:"FAT atypical cadherin 1" OR TITLE:"Protocadherin Fat 1" OR ABSTRACT:"Protocadherin Fat 1" OR TITLE:"CDHF7" OR ABSTRACT:"CDHF7" OR TITLE:"CDHR8" OR ABSTRACT:"CDHR8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAT1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCASP8
Shares Nasopharyngeal carcinoma, Cervical cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetKDM6A
Shares Lung cancer (all types), Oesophageal cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetLRP1B
Shares Lung cancer (all types), Oesophageal cancer, Breast cancer (all types), CIViC.
- TargetZNF521
Shares Nasopharyngeal carcinoma, Lung cancer (all types), Oesophageal cancer, Cervical cancer.
- TargetMYH9
Shares Lung cancer (all types), Oesophageal cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetTP63
Shares Lung cancer (all types), Cervical cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetPIK3CB
Shares Lung cancer (all types), Bladder & urothelial cancer, Breast cancer (all types), CIViC.
- TargetMAPK1
Shares Lung cancer (all types), Cervical cancer, Breast cancer (all types), CIViC.